Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-rhPSMA-10.1 after PSMA PET-guided EBRT in Biochemically Recurrent Prostate Cancer
NCT06105918Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Nov 2023
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium (177Lu) rhPSMA-10.1 in prostate cancer (PCa), sponsored by Emory University. Primary endpoint: Incidence of radiotherapy and radioligand therapy related adverse events. Started Nov 2023; status: active, not recruiting.
02
Drugs
lutetium (177Lu) rhPSMA-10.1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06105918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105918.